PTC/SB/88s (08-03.)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nd to a collection of information unless it contains a valid OMB control number.

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number			
	Filing Date			
	First Named Inventor Antho		nony Jarvis	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	41331	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	4420581		1983-12-13	McFarlane et al.			
	2	4408004		1983-10-04	Pengilly			
If you wish	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan
	1	20040180159		2004-09-16	Neal et al.			
	2	20060105129		2006-05-18	Xia			
	3	20060106192		2006-05-18	Xsa			
	4	20060106146		2006-05-18	Xsa			
If you wish	h to a	dd additional U.S. Publi:			n information please click the Ad	L d button		
				FOREIGN PAT	TENT DOCUMENTS		Remove	

Application Number | Filing Date | Filing Date | Filing Date | Filing Managed Inventor | Authority Janvis | Art Unit | Examiner Name | Attorney Docket Number | Attorney Docket

Examiner Initial*	Cite No	Foreign Documen Number ³	t Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	0 429 311	EP	A2	1991-05-29	Imperial Chemical Industries PLC		
If you wisl	h to a	dd additional Foreig	n Patent Docume	ent citation	information p	please click the Add butto	n Add	
			NON-PAT	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Τs		
	1	International Search	h Report dated Jun	e 15, 2005	(PCT/GB2005/	001231).		
If you wis	h to a	dd additional non-p	atent literature do	cument cit	tation informa	tion please click the Add	button Add	
				EXAMINE	R SIGNATUR	RE		
Examiner	Signa	ture				Date Considered		
*FXAMIN	FR: In	itial if reference co	nsidered whether	or not cits	ation is in con	formance with MPEP 609	Draw line through a	

See Kind Codes of USPTO Patent Documents at sweru(SPTO_GOV) or MPEP 901.04. Enter office that issued the document, by the how-left or (WIPO) Standard ST3.) For Lapraesee patent documents, the schication of the year of the region or the Emperor may preced the sents included the plant document. If kind of coursent by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. Speciation is to place a check mark here if Emplois assume precision is astructed.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date Filing Date First Number Inventor Arethorny Janvis Art Unit Examiner Name Attorney Cooket Number | 41331

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/paul a serbinowski/	Date (YYYY-MM-DD)	2006-09-28			
Name/Print	Paul A. Serbinowski	Registration Number	34429			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1436, Alexandria, V.32.11.4450 D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211.4450

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.